TY - JOUR
T1 - microRNA-378a-5p iS a novel positive regulator of melanoma progression
AU - Tupone, Maria Grazia
AU - D’Aguanno, Simona
AU - Di Martile, Marta
AU - Valentini, Elisabetta
AU - Desideri, Marianna
AU - Trisciuoglio, Daniela
AU - Donzelli, Sara
AU - Sacconi, Andrea
AU - Buglioni, Simonetta
AU - Ercolani, Cristiana
AU - Biagioni, Alessio
AU - Fibbi, Gabriella
AU - Fattore, Luigi
AU - Mancini, Rita
AU - Ciliberto, Gennaro
AU - Blandino, Giovanni
AU - Del Bufalo, Donatella
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Evaluating the expression levels of miR-378a-5p both in a large melanoma patient cohort from The Cancer Genome Atlas database and in melanoma patients from our Institute, we found that miR-378a-5p is upregulated in metastatic melanoma specimens. miR-378a-5p expression was also increased in melanoma cells resistant to target therapy, and decreased in response to drug treatment. We also demonstrated that overexpression of miR-378a-5p enhances in vitro cell invasion and migration, and facilitates the ability of melanoma cells to form de novo vasculogenic structures. While performing downstream targeting studies, we confirmed the ability of miR-378a-5p to modulate the expression of known target genes, such as SUFU, FUS-1, and KLF9. Luciferase-3′UTR experiments also identified STAMBP and HOXD10 as new miR-378a-5p target genes. MMP2 and uPAR, two HOXD10 target genes, were positively regulated by miR-378a-5p. Genetic and pharmacologic approaches inhibiting uPAR expression and activity evidenced that the in vitro tumor-promoting functions of miR-378a-5p, were in part mediated by uPAR. Of note miR-378a-5p was also able to increase VEGF, as well as in vitro and in vivo angiogenesis. Finally, genetic and pharmacologic modulation of Bcl-2 evidenced Bcl-2 ability to regulate miR-378a-5p expression. In conclusion, to the best of our knowledge, this is the first study demonstrating that miR-378a-5p acts as an oncogenic microRNA in melanoma.
AB - Evaluating the expression levels of miR-378a-5p both in a large melanoma patient cohort from The Cancer Genome Atlas database and in melanoma patients from our Institute, we found that miR-378a-5p is upregulated in metastatic melanoma specimens. miR-378a-5p expression was also increased in melanoma cells resistant to target therapy, and decreased in response to drug treatment. We also demonstrated that overexpression of miR-378a-5p enhances in vitro cell invasion and migration, and facilitates the ability of melanoma cells to form de novo vasculogenic structures. While performing downstream targeting studies, we confirmed the ability of miR-378a-5p to modulate the expression of known target genes, such as SUFU, FUS-1, and KLF9. Luciferase-3′UTR experiments also identified STAMBP and HOXD10 as new miR-378a-5p target genes. MMP2 and uPAR, two HOXD10 target genes, were positively regulated by miR-378a-5p. Genetic and pharmacologic approaches inhibiting uPAR expression and activity evidenced that the in vitro tumor-promoting functions of miR-378a-5p, were in part mediated by uPAR. Of note miR-378a-5p was also able to increase VEGF, as well as in vitro and in vivo angiogenesis. Finally, genetic and pharmacologic modulation of Bcl-2 evidenced Bcl-2 ability to regulate miR-378a-5p expression. In conclusion, to the best of our knowledge, this is the first study demonstrating that miR-378a-5p acts as an oncogenic microRNA in melanoma.
UR - http://www.scopus.com/inward/record.url?scp=85079501063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079501063&partnerID=8YFLogxK
U2 - 10.1038/s41389-020-0203-6
DO - 10.1038/s41389-020-0203-6
M3 - Article
AN - SCOPUS:85079501063
VL - 9
JO - Oncogenesis
JF - Oncogenesis
SN - 2157-9024
IS - 2
M1 - 22
ER -